Experiences of renal transplants from donors with renal cell carcinoma after ex vivo partial nephrectomy

  • Lim, Sung Yoon (Department of Internal Medicine, Korea University Medical College) ;
  • Kim, Myung Gyu (Department of Internal Medicine, Korea University Medical College) ;
  • Park, Kwon Tae (Department of Surgery, Korea University Medical College) ;
  • Jung, Cheol Woong (Department of Surgery, Korea University Medical College)
  • Received : 2016.09.22
  • Accepted : 2016.11.29
  • Published : 2017.05.01


Purpose: Routine evaluation of kidney donors occasionally reveals an incidental renal mass with an otherwise satisfactory kidney function. The use of such a kidney with an enhancing mass for transplantation is a matter of debate owing to a possible risk of transmission of donor malignancies. We report our experience of kidney transplants from donors with renal cell carcinoma, after ex vivo resection of the renal mass. Methods: Two women aged 44 and 56 years were diagnosed with enhancing renal masses measuring 0.9 cm and 0.7 cm, respectively, during donor evaluation for kidney transplantation. Both patients and their families were informed of a potential risk of recurrent renal cell carcinoma following transplantation. Results: Renal function test results of both donors satisfied the living donor selection criteria. Laparoscopic live donor nephrectomy was performed with ex vivo resection of renal masses on the bench table. Immediate pathological analysis revealed a renal cell carcinoma with a margin of normal renal parenchyma before transplantation. Regimens based on mammalian target of rapamycin inhibitors, which are known for their antitumoral properties, were used for immunosuppression in both recipients. None of the recipients showed recurrence or metastasis during the follow-up period, which was longer than 3 years after transplantation. Conclusion: In light of the ongoing shortage of kidney donors, kidneys with small renal cell carcinoma could be considered for transplantation after appropriate removal of the lesion, with a very low risk of recurrent disease.


  1. Johnson DW, Herzig K, Purdie D, Brown AM, Rigby RJ, Nicol DL, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000; 69:794-9.
  2. Audard V, Matignon M, Dahan K, Lang P, Grimbert P. Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transpl Int 2008;21:11-7.
  3. Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000;11: 917-22.
  4. Becker F, Siemer S, Humke U, Hack M, Ziegler M, Stockle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients. Eur Urol 2006;49:308-13.
  5. Nalesnik MA, Woodle ES, Dimaio JM, Vasudev B, Teperman LW, Covington S, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant 2011;11:1140-7.
  6. Nicol D. Issues in the diagnosis of renal cell carcinoma. BJU Int 2000;86:298-303.
  7. Crepel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, et al. A populationbased comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. Urology 2010;76:883-8.
  8. Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer 2010;116:2316-21.
  9. Van Poppel H. Efficacy and safety of nephron-sparing surgery. Int J Urol 2010;17: 314-26.
  10. Kim JY, Ruckle HC, Ramin SA. Partial nephrectomy for renal cell carcinoma in an allograft kidney 15 years after transplantation. J Urol 2001;165:1205.
  11. Lamb GW, Baxter GM, Rodger RS, Aitchison M. Partial nephrectomy used to treat renal cell carcinoma arising in a live donor transplant kidney. Urol Res 2004; 32:89-92.
  12. Neipp M, Schwarz A, Pertschy S, Klempnauer J, Becker T. Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up. Clin Transplant 2006; 20:147-50.
  13. Thomalla JV. Renal cell carcinoma in a renal allograft successful treatment with 5 year follow-up. Clin Med Res 2004;2:151-3.
  14. Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, et al. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. BJU Int 2008;102:188-92.
  15. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-24.
  16. Mannami M, Mannami R, Mitsuhata N, Nishi M, Tsutsumi Y, Nanba K, et al. Last resort for renal transplant recipients, 'restored kidneys' from living donors/patients. Am J Transplant 2008;8:811-8.
  17. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007;370:59-67.
  18. Russ GR. Optimising the use of mTOR inhibitors in renal transplantation. Transplant Res 2013;2(Suppl 1):S4.
  19. Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009; 9:231-41.
  20. Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006;38:358-61.